

PTOSBosa (03-09)
Approved for use through 0x/30/2000, Mod 8051-0031
U.S. Patent and Trademan Critics; U.S. DEPARTMENT OF COMMERCE
on Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OUS control number.

Substitute for form 1449/PTO

Sheet

Examiner

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use es many sheets as necessary)

Application Number	10/586,892
Filing Date	February 9, 2007
First Named Inventor	David S. Lawrence
Art Unit	1636
Examiner Name	Jennifer Ann Dunston
Attorney Docket Number	96700/1160

U. S. PATENT DOCUMENTS Name of Petentee or Pages, Columns, Lines, Where Document Number **Publication Date** Examine MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Initials* No Figures Appear Number-Kind Code² of Annu US- 6,458,538 B1 1 10-01-2002 Beckmann et al. US- 6,486,305 B1 11-26-2002 Peltz et al 2 3 US- 6,630,294 B1 10-07-2003 Peltz et al. US-US-US US-US-US-US-US-US-

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Dete	Name of Petentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevent Pesseges	1
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
						L
						-
						L
						L
					1	

Signature |
SZAMINES: This if inference considered, whether or not citation is in conformance with MPEP 606. Drive line through clatter, in our incommence and not considered include copy of the form with next communication to applicant. "Applicants" a virtue clatical resignation number replants." See Kinds Codes of MPEP Patient Documents of years and page, our PMEP 90 100 4. Enter Offician the issued the document, by the volvable code (WIPO Standard ST.s). "For more considered includes the indication of the year of the regin of the Emperor must proced the serial number of the patient document. "And of document by the volvable code (WIPO Standard ST.s)." For more provided in the patient document, which is considered in the page of the page o

Transition is extended.

This collection of information is required by 37 CFR 1 97 and 1.98. The information is required to obtain or retain e-benefit by the public which is to file (and by the USPTO to process) an eppiration. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Including pathering, preparing, and submitting the completed expiration from the USPTO. There will vary depending upon the individual capacities on the emount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US. Patent and Trasemant Office, PO. 80. 1416, Alexandria, VA.2213-145. DO NOT SEED PRESS NO FEO WHITEET FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1459.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08b (03-09)

Approved for use through 04/30/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/586,892	
INFORMATION DISCLOSURE				Filing Date	February 9, 2007	
STATEMENT BY APPLICANT		First Named Inventor	David S. Lawrence			
(Use as many sheets as necessary)			cessand	Art Unit	1636	
(USB BS INDITY SHOULD BE HUCCESSARY)		Examiner Name	Jennifer Ann Dunston			
Sheet	2	of	4	Attorney Docket Number	96700/1160	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	4	ANDREASSI C et al., entitled "Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients," Human Molecular Genetics,	
		2001, Vol. 10, No. 24, 2841-2849.	
	5	BURATTI E et al., entitled "Can a 'patch' in a skipped exon make the pre-mRNA splicing machine run better?" Trands in Molecular Medicine, Vol. 9, No. 6, June 2003, 229-232.	
	6	CARTEGNI L et al., entitled "Correction of disease-associated exon skipping by synthetic exon-specific activators," Nature Structural Biology, Vol. 10, No. 2, February 2003,	
		120-125.	
	7	CHANG J G, et al., entitled "Treatment of spinal muscular atrophy by sodium butyrate," PNAS, August 14, 2001, Vol. 98, No. 17, 9808-9813.	
	8	CLANCY J P et al., entitled "Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis," Am J Respir Crit Care Med, Vol 163,	
		1683-1692, 2001.	
	9	KAUFMAN R J, entitled "Correction of genetic disease by making sense from nonsense," The Journal of Clinical Investigation, August 1999, Vol. 104, No. 4, 367-368.	
	10	KHOO B et al., entitled Putting some spine into alternative splicing," Trends in Biotechnology, Vol. 21, No. 8, August 2003, 328-330.	

Examiner	Date	
Signature	Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 6	09. Drawline through o	station if not in conformance and not

considered, include copy of this form with next communication to appeared.

A popilizaria surjuic surface design and communication of appeared by a popular surface, and here if popular insurger. Transition is established.

A popular surface, and a popular surface and a popular surface and a popular surface and a popular surface and a popular surface. The surface and a popular surface and a surface surface and a popular surface and a pop

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

considered. Include copy of this form with next communication to epplicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08b (03-09)

Approved for use through 04/30/2009, OMB 0851-0031
U.S. Patent end Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known			
333311101311111111111111111111111111111	Application Number	10/586,892		
INFORMATION DISCLOSURE	Filing Date	Feburary 9, 2007		
STATEMENT BY APPLICANT	First Named Inventor	David S. Lawrence		
(Use as many sheets as necessary)	Art Unit	1636		
tose as many should as necessary	Examiner Name	Jennifer Ann Dunston		
Sheet 3 of 4	Attorney Docket Number 96700/1160			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	11	LUKACS G L et al., entitled "Pharmacologic Approaches to Correcting the Basic Defect in Cystic Fibrosis," N Engl J Med 349;15, 1401-1404, October 9, 2003.	
	12	MANKIN A S et al., entitled "Baby, don't stop!" Nature Genetics, Vol. 23, September 1999, 8-10.	
	13	POLITANO L et al., entitled "Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results," Acta Myol, 2003, May;22(1):15-21, Abstract Only.	
	14	SKORDIS L A et al., entitled "Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts,"	
		PNAS, April 1, 2003, Vol. 100, No. 7, 4114-4119.	
	15	WILSCHANSKI M et al., entitled "A Pilot Study of the Effect of Gentamicin on Nasal Potential Difference Measurements in Cystic Fibrosis Patients Carrying Stop Mutations,"	
		Am J Respir Crit Care Med, Vol. 161, 860-865, 2000.	
	16	WILSCHANSKI M et al., entitled "Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations,"	
		N Engl J Med 349;15, Ocotober 9, 2003, 1433-1441.	
	17	XI B et al., entitlted "Enhanced Production of Functional Proteins from Defective Genes," J. Am. Chem. Soc., 2004, 126, 5660-5661 & Supporting Info. S1-S12	

Examiner		Date	
Signature		Considered	
EXAMINER: Initial	if reference considered, whether or not citation is in conformance with MPEP 60	Draw line through o	itation if not in conformance and not

considered. Include copy of this form with next communication to epplicant.

considered, include copy of this form with next communication to applicate.

1. Applicated is notice cuttion designation number (optional). 2. Applicant is not pose a check mark term (E rogical) in required in the statistic of the control of the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08b (03-09)

Approved for use through 04/30/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

..- '

Examiner

Substitute for form 1449/PTO	Complete if Known		
Substitute for form 14457110	Application Number	10/586,892	
INFORMATION DISCLOSURE	Filing Date	February 9, 2007	
STATEMENT BY APPLICANT	First Named Inventor	David S. Lawrence	
(Usa as many sheets as necessary)	Art Unit	1636	
(USB BS Many Sheets BS necessary)	Examiner Name	Jennifer Ann Dunston	
Sheet 4 of 4	Attorney Docket Number	96700/1160	

_	0	NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	18	"PCT NOTIFICIATION CONCERNING TRANSMITTAL OF COPY OF INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY," Issued by	
		The International Bureau of WIPO on September 21, 2006 in connection with International Patent Application No. PCT/US2005/007365, 6 pages.	

EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 60	9. Drawline through o	itation if not in conformance and not
Signature	/Jennifer Dunston/ (12/11/2009)	Considered	
Examiner		Date	

considered. Include copy of this form with next communication to applicant,

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

Commissioner Order (1900) and the Commissioner (1900) and th